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Summary 
We have developed a method to analyze the functionality of putative TA loci by expressing 
them in E. coli. Here we describe the procedure for cloning recombinant TA genes into 
inducible plasmids and expressing these in E. coli. Following expression, toxicity, 
resuscitation of growth and changes in persister cell formation are assayed. This can confirm 
whether predicted TA loci are active in E .coli and whether expression can affect persister 
cell formation.  
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1. Introduction 
Toxin-antitoxin (TA) systems are found in many bacterial species and typically consist of a 
gene pair coding for a toxin and antitoxin gene. The toxins can typically bind and inhibit the 
function of a cellular target causing inhibition of bacterial growth [1]. The antitoxin gene 
codes for either a protein or an RNA molecule that inhibits the activity of the toxin under 
normal cellular conditions. One role for TA systems is in the formation of bacterial persister 
cells [2]. Bacterial persisters are a sub-population of cells that can tolerate and survive 
antibiotic or stress treatment, whereas the majority of the population is killed [3]. Expression 
of TA toxins can increase the population of tolerant persister cells [4,5].  An increase in 
persistence has been best demonstrated in E. coli following expression of a variety of toxins. 
One of the first examples of this was ampicillin treatment of E. coli cultures expressing the 
TA toxin HipA from an arabinose driven pBAD promoter [6]. Other toxins such as RelE, TisB 
and HicA have also been tested using similar methodology, expressing the toxin from an 
inducible promoter and then treating with antibiotic [7,5,4]. The method we have developed 
permits testing on the functionality of putative or predicted TA systems though expression in 
E. coli. Predicted TA systems native to the E. coli host or from other bacteria, such as 
Burkholderia pseudomallei, can be expressed in E. coli MG1655 [8,4].  The method requires 
cloning of putative toxin and antitoxin genes into separate compatible and inducible plasmids 
and firstly assaying for growth arrest/ reduction in culturability following expression of the 
toxin and resuscitation/restoration of growth following expression of the antitoxin. Following 
assessment of these phenotypes, the methodology can be implemented to assay for the 
effect of TA expression on the persistence of E. coli following treatment with various 
antibiotics. Failure of E. coli to express cloned recombinant genes and differences between 
toxin target(s) in the native host compared to target(s) in E. coli are potential limitations of 
this technique. However, in using E. coli as a host, a safe and high throughput method has 
been developed to screen a variety of predicted TA systems from a range of bacteria for 
functionality. This method can be used to down select TA genes candidates for further 
phenotypic study in the native host or for structural studies.  
2. Materials 
1. E. coli MG1655 strain (F-, lambda-, rph-1) 
2. Expression plasmids e.g. pBAD/his (Invitrogen) and pME6032 
3. Antibiotics for plasmid selection, e.g. ampicillin (100 mg/ml) and tetracycline (15 
mg/ml) dissolved in water 
4. PCR reagents for gene amplification  
5. Restriction enzymes for cloning 
6. LB: Weigh 5 g Bacto-tryptone, 2.5 g yeast extract, 5 g NaCl and dissolve in 500 ml 
water. Autoclave for sterilisation 
7. LB agar: Weigh 5 g Bacto-tryptone, 2.5 g yeast extract, 5 g NaCl, 7.5 g agar and 
dissolve in 500 ml water. Autoclave for sterilisation. 
8. Arabinose 20% solution in water 
9. Glucose 20% solution in water 
10. Isopropyl β-D-1-thiogalactopyranoside (IPTG) 1 M solution in water 
11.  Universal tubes 
12. 200 ml Conical flasks 
13. 96-well plates 
14. 24-well plates 
15. Cuvettes: 1 cm diameter 
16. 1.5 ml Eppendorf tubes 
17. Spectrophotometer set for measurement at 590nm 
18. Centrifuge(s), capable of speeds of 3000 x g for universal tubes and 13,000 x g for 
1.5 ml Eppendorf tubes 
 
3. Methods 
3.1 Cloning into expression vectors 
1. PCR amplify putative toxin or antitoxin genes using genomic DNA as a template and 
primers containing appropriate restriction sites 
2. Clone toxin gene(s) into an inducible expression plasmid such as the pBAD/his 
vector (Invitrogen) via appropriate restriction sites (fig 1a) (See Note 1). 
3. Clone antitoxin genes into a different inducible expression plasmid such as the 
pME6032 vector via appropriate restriction sites within the multiple cloning sites (fig 
1b), (See Note 2). 
3.2 Toxicity assay  
The following protocols assume the use of the pBAD/his and pME6032 plasmids. If other 
plasmids are used, change the antibiotics for plasmid selection and sugar 
inducers/repressors as appropriate. 
1. Inoculate 5 ml of LB broth containing 100 µg/ml ampicillin with E. coli harbouring 
pBAD with cloned toxin gene and incubate at 37oC, 200 rpm for 16 hours.  
2. Dilute the culture 1:100 in 40 ml of fresh LB in a 200 ml conical flask supplemented 
with 100 µg/ml ampicillin. Grow cultures at 37oC, 200 rpm until reaching an OD590nm 
of ~0.1. (See Note 3) 
3.  Aliquot 2 x 10 ml of culture into universal tubes and supplement with either 0.2% 
(w/v) glucose or 0.2% (w/v) arabinose to repress or induce expression from the 
pBAD promoter respectively. Incubate cultures at 37oC, 200 rpm. 
4. At hourly intervals, remove 1 ml of culture (or 100 µl and mix with 900 µl LB for 1:10 
dilution)  and add to a cuvette to record the OD590nm using a spectrophotometer 
5. In parallel, remove 10 µl of culture and set up a serial dilution in a 96-well plate 
containing LB. Carry out a dilution range from 10-1-10-6. Spot plate the dilution range 
onto LB plates containing 100 µg/ml ampicillin and incubate plates statically at 37oC 
until colonies are visible for enumeration (fig 2). 
3.3 Co-expression assay 
1. Inoculate 5 ml of LB broth containing 100 µg/ml ampicillin, 15 µg/ml tetracycline with 
E. coli harbouring pBAD/toxin gene and pME6032/antitoxin gene and incubate at 
37oC, 200 rpm for 16 hours.  
2. Dilute the culture 1:100 in 50 ml of fresh LB in a 200 ml conical flask supplemented 
with 100 µg/ml ampicillin, 15 µg/ml tetracycline. Grow cultures at 37oC, 200 rpm until 
reaching an OD590nm of ~0.1. 
3. Aliquot 4 x 10 ml of culture into universal tubes and supplement with either 0.2% 
(w/v) glucose or 0.2% (w/v) glucose, 25 mM IPTG or 0.2% (w/v) arabinose or 0.2% 
arabinose, 25mM IPTG to repress or induce expression from the pBAD and 
pME6032 promoters. Incubate cultures at 37oC, 200 rpm. 
4. At hourly intervals, remove 1 ml of culture (or 100 µl and mix with 900 µl LB for 1:10 
dilution)  and add to a cuvette to record the OD590nm using a spectrophotometer 
5. In parallel, remove 10 µl of culture and set up a serial dilution in a 96-well plate 
containing LB. Carry out a dilution range from 10-1-10-6. Spot plate the dilution range 
onto LB plates containing 100 µg/ml ampicillin, 15 µg/ml tetracycline and incubate 
plates statically at 37oC until colonies are visible for enumeration. (Fig 3). 
3.4 Resuscitation assay  
1. Inoculate 5 ml of LB broth containing 100 µg/ml ampicillin, 15 µg/ml tetracycline with E. 
coli harbouring pBAD/toxin gene and pME6032/antitoxin gene and incubate at 37oC, 200 
rpm for 16 hours.  
2. Dilute the culture 1:100 in 60 ml of fresh LB in a 200 ml conical flask supplemented with 
100 µg/ml ampicillin, 15 µg/ml tetracycline. Grow cultures at 37oC, 200 rpm until reaching 
an OD590nm of ~0.1. 
3. Aliquot 2 x 25 ml of culture into 200 ml conical flasks and supplement with either 0.2% 
(w/v) glucose or 0.2% (w/v) arabinose to repress or induce expression from the pBAD 
promoter respectively. Incubate cultures at 37oC, 200 rpm for 2 hours (T2). 
4. Aliquot 2 x 10 ml of each culture into universal tubes and supplement one with 25 mM 
IPTG to induce antitoxin expression from the pME6032 promoter. Incubate cultures at 
37oC, 200 rpm for a further 2 hours (T4). (See Note 4) 
5. At hours T0, T2 and T4 remove 1 ml of culture (or 100 µl and mix with 900 µl LB for 1:10 
dilution) and add to a cuvette to record the OD590nm using a spectrophotometer. In 
parallel, remove 10 µl of culture and set up a serial dilution in a 96-well plate containing 
LB. Carry out a dilution range from 10-1-10-6. Spot plate the dilution range onto LB plates 
containing 100 µg/ml ampicillin, 15 µg/ml tetracycline and incubate plates at statically at 
37oC until colonies are visible for enumeration (fig 4). 
3.5 Persister assay 
1. Inoculate 5 ml of LB broth containing 100 µg/ml ampicillin, 15 µg/ml tetracycline with 
E. coli harbouring pBAD/toxin gene and pME6032/antitoxin gene and incubate at 
37oC, 200 rpm for 16 hours.  
2. Dilute the culture 1:100 in 30 ml of fresh LB in a 200 ml conical flask supplemented 
with 100 µg/ml ampicillin, 15 µg/ml tetracycline. Grow cultures at 37oC, 200 rpm until 
reaching an OD590nm of ~0.1. 
3. Aliquot 2 x 10 ml of culture into universal tubes and supplement with either 0.2% 
(w/v) glucose or 0.2% (w/v) arabinose to repress or induce expression from the 
pBAD promoter respectively. Incubate cultures at 37oC, 200 rpm for 3 hours. 
4. Standardise cultures to 2 x 108 CFU/ml (OD590nm 0.5) in a 5 ml volume and add 500 
µl aliquots to a 24 well plate.   
5. Add 500 µl of LB antibiotic stock at 200 x minimum inhibitory concentration (MIC) to 
each of the wells. (This gives 108 CFU/ml and 100 X MIC antibiotic per well) (See 
Note 5). 
6. Add 10 µl of standardised culture from step 4 to a 96-well plate containing LB for 
serial dilution. Carry out a dilution range from 10-1-10-6. Spot plate the dilution range 
onto LB plates containing 100 µg/ml ampicillin, 15 µg/ml tetracycle, 1 mM IPTG and 
incubate plates at statically at 37oC until colonies are visible for enumeration. (See 
Note 6) 
7. Incubate 24 well persister assay plate statically at 37oC for 24 hours. 
8. Remove cultures from 24 well plate and add to 1.5 ml Eppendorf tubes. 
9. Centrifuge the tubes for 7 minutes at max speed in a microcentrifuge 
10. Remove the supernatant and then re-suspend the pellet in fresh LB 
11. Serial dilute the cultures in LB using a dilution range of 100-10-4 in a 96 well plate. 
Spot plate the dilution range onto LB plates containing 100 µg/ml ampicillin, 15 µg/ml 
tetracycle, 1 mM IPTG and incubate plates statically at 37oC until colonies are visible 
for enumeration. 
12. Persister frequency is determined as CFU post antibiotic treatment divided by CFU 
pre antibiotic treatment. (See Note 7) (Fig 6). 
4. Notes 
1. If using the pBAD/ his vector clone into the NcoI sites and EcoRI/HindIII sites to 
create a non-his tagged construct or SacI and EcoRI/HindIII to create a his-tagged 
construct. The N-terminal his tag, although useful for protein purification and Western 
blotting, may interfere with the function of the toxin or shield the antitoxin binding site. 
It is advisable to make both a his tagged and non his tagged version of the toxin for 
phenotypic analysis. 
2. Both inducible expression plasmids need to be in different incompatibility groups, as 
it is not possible to maintain two different plasmids in a single cell, which use the 
same mechanism for replication. The plasmids described in this manuscript fall into 
the pMB1 group (pBAD/his) and p15A group (pME6032). Both plasmids have a 
similar copy number per cell. 
3. If cultures of E. coli harbouring pBAD with a cloned toxin are growing slower than a 
control E. coli harbouring empty pBAD, add 0.2% glucose to the media to prevent 
leaky expression from the pBAD promoter. Cultures should be harvested and re-
suspended in fresh media prior to adding 0.2% arabinose if glucose is added during 
the initial growth step. 
4. If addition of IPTG, to induce expression of the antitoxin from pME6032, fails to 
resuscitate growth of toxin induced cultures, a wash step should be added to the 
protocol. Prior to addition of IPTG, harvest cells by centrifugation at 3000 x g for 10 
minutes. Remove the supernatant and re-suspend the pellet in the same volume of 
fresh LB. Add IPTG and fresh antibiotic. 
5. Some antibiotic stocks, such as ceftazidime, need to be made fresh every time as 
they are susceptible to degradation and will not work properly after pro-longed 
storage.  
6. 1 mM IPTG is included in the plates to induce antitoxin expression from the pME6032 
promoter. This is to re-awaken/ resuscitate any non-culturable/ dormant cells induced 
by toxin expression. This is to achieve a more accurate measure of the total number 
of viable cells. If the total cell numbers are lower than expected the IPTG 
concentration should be increased. 
7. Time 0 counts should be divided by 2, since only half of the standardised culture is 
added to the persister assay. 
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Figure 1. Expression plasmid maps. Key features such as antibiotic resistance genes., 
multiple cloning sites and origins of replication are shown A) pBAD/his. B) pME6032  
  
  
 
Figure 2. Effect of toxin expression from the pBAD/his vector on E. coli growth. 0.2% 
glucose or arabinose was used to repress or induce expression of the toxin respectively. A) 
Growth measured by optical density. B) Growth measured by CFU counts. Reproduced  
from [8] with permission. 
  
  
Figure 3 Co-expression of toxin and antitoxin from different inducible promoters in E. coli 
and the change in the number of culturable cells. 0.2% glucose or 0.2% arabinose was used 
to repress or induce expression of the plasmid cloned toxin respectively. 25 mM IPTG was 
used to induce expression of the plasmid cloned antitoxin. Reproduced from [8] with 
permission. 
  
  
 
Figure 4. Resuscitation of growth by antitoxin expression.  0.2% glucose or 0.2% arabinose 
was used to repress or induce expression of the plasmid cloned toxin respectively. 2 hours 
later 25 mM IPTG was used to induce expression of the plasmid cloned antitoxin before 
plating for enumeration. Reproduced from [8] with permission. 
  
  
 
Figure 5. Persister cell frequency following 24 hour treatment of E. coli cultures with 100 x 
MIC ciprofloxacin. Toxin expression was repressed with 0.2% glucose or induced with a 
range of arabinose concentrations for 3 hours before ciprofloxacin treatment. Reproduced 
from [4] with permission. 
 
